Day Two At BIO CEO: Deal Value Up, Deal Volume Down
This article was originally published in The Pink Sheet Daily
Executive Summary
The Let’s Make a Deal panel looked forward to more big product-focused Genzyme/Alnylam type deals in 2014 in a deal landscape changed by a robust pubic market and by caution on the part of big pharma; BIO chair Rachel King on 2014 priorities; Stallergenes prepares to launch Oralair